Breakthroughs in Schizophrenia Treatment With Muscarinic Agents
This activity is supported by an educational grant from Bristol Myers Squibb.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Bristol Myers Squibb.
Activity Description
“Breakthroughs in Schizophrenia Treatment With Muscarinic Agents: A Rapid Response From the NEI Congress” offers clinicians an up-to-date analysis of innovative treatments that address longstanding challenges in schizophrenia management. Traditional therapies often fall short in managing the cognitive impairment and negative symptoms of schizophrenia, while posing risks of serious side effects. This CE program highlights novel muscarinic agents that present a newly approved, promising alternative.
In this rapid-response format, expert faculty examine key abstracts from the Neuroscience Education Institute (NEI) Congress, focusing on muscarinic agents such as xanomeline-trospium and emraclidine, which show potential in targeting schizophrenia’s cognitive and negative symptom domains. Through expert-led discussions on mechanisms, efficacy, and emerging evidence, participants will explore how these agents fit into conventional treatment paradigms, equipping them with knowledge to make informed decisions on the adoption of muscarinic agents in clinical practice.
Target Audience
The intended audience for this activity is psychiatrists, pharmacists, psychiatric nurse practitioners, psychiatric physician associates, and other healthcare professionals involved in the management of patients with schizophrenia.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize the rationale for use of muscarinic agents in patients with schizophrenia, including the potential benefit on both the positive and negative symptoms.
- Summarize the latest evidence regarding muscarinic agents in the management of patients with schizophrenia.
- Recognize how muscarinic agents fit into traditional treatment paradigms.
Activity Chair
Leslie Citrome, MD, MPH
Clinical Professor of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, NY
Faculty
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Professor of Child and Adolescent Psychiatry
Charité Universitatsmedizin
Berlin, Germany
Jonathan M. Meyer, MD, DLFAPA
Voluntary Clinical Professor
Department of Psychiatry
University of California, San Diego
San Diego, CA
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Linda A. Giarraputo, BS, PA-C
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/16/2025. PAs should only claim credit commensurate with the extent of their participation.
This program is acceptable for 1.0 contact hour of ACPE Continuing Education Credit. The ACPE Universal Program Number is JA0006104-0000-24-085-H01-P, effective 11/17/2024. This is a knowledge-based activity, and there is no fee to attend.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, November 17, 2024, to November 16, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate, Statement of Continuing Pharmacy Education Credit, or AAPA Category 1 CME certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Leslie Citrome, MD, MPH
Consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, BMS, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, Impel, INmune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe, Neumora, Neurelis, Neurocrine Biosciences, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumimoto/Sunovion, Supernus, Teva, University of Arizona
Speaker Contracted by Ineligible Company: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, BMS, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva
Individual Stocks (publicly traded): Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer
Christoph U. Correll, MD
Advisor: AbbVie, Allergan, Angelini, BMS, Boehringer Ingelheim, Compass Pathways, Gedeon Richter, Janssen/J&J Vision, Karuna, LB Pharma, Life Sciences, Lundbeck, MedinCell, Merck, Neurelis, Neurocrine Biosciences, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Sunovion, Supernus, Teva, Vertex, Viatris
Consultant: AbbVie, Acadia, Alkermes, Allergan, Angelini, Axsome, BMS, Boehringer Ingelheim, Cardio Diagnostics, Cerevel, Compass Pathways, Gedeon Richter, Holmusk, Intra-Cellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lilly, Lundbeck, MedAvante-ProPhase, MedinCell, Medscape, Merck, MindPax, Mylan, Neurocrine Biosciences, Noven, Otsuka, Pfizer, Pharmabrain, PPD Biotech, Recordati, Relmada, Rovi, Saladax, Sanofi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, Viatris
Speaker Contracted by Ineligible Company: AbbVie, Angelini, Aristopharma, BMS, Boehringer Ingelheim, Cerevel, Damitsa, Gedeon Richter, Hikma, Intra-Cellular Therapies, Janssen/J&J, Karuna, Lundbeck, Mitsubishi Tananbe, Mylan, Otsuka, Recordati, Seqirus, Sunovion, Tabuk, Takeda, Viatris
Independent Research Contractor: Boehringer Ingelheim, Janssen, Takeda
Stock Options: Küleon Biosciences, LB Pharma, MindPax
Jonathan M. Meyer, MD, DLFAPA
Consultant: Alkermes, Axsome, BMS, Cerevel, ITCI, Neurocrine, Relmada, Sumitomo Pharma, Teva
Speaker Contracted by Ineligible Company: AbbVie, Alkermes, Axsome, BMS, ITCI, Neurocrine, Sumitomo Pharma, Teva
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Linda A. Giarraputo, BS, PA-C
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com